Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
2 "Rupert Leong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study
Robert Gilmore, Richard Fernandes, Imogen Hartley, Arteen Arzivian, Rupert Leong, Bridgette Andrew, Abhinav Vasudevan, Tessa Greeve, Gregory Thomas Moore, Steven Kim, Daniel Lightowler, Abhey Singh, Gillian Mahy, Aditya Mithanthaya, Kannan Venugopaul, Sangwoo Han, Robert Bryant, Jack West, Jonathan Segal, Britt Christensen, Crispin Corte, Nik Ding, Yoon-Kyo An, Jakob Begun
Received August 12, 2024  Accepted October 7, 2024  Published online December 20, 2024  
DOI: https://doi.org/10.5217/ir.2024.00127    [Epub ahead of print]
AbstractAbstract PDFPubReaderePub
Background/Aims
Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulcerative colitis in a real-world population.
Methods
Patients that commenced upadacitinib for moderate-to-severe ulcerative colitis from September 2022 until March 2023 were identified at 13 inflammatory bowel disease centers across Australia. Clinical, biochemical, endoscopic, and intestinal ultrasound outcomes were recorded retrospectively at baseline, week 8, and week 16.
Results
One hundred and fifty-two patients (61 female [40%], median age 38 years [interquartile range, 28–50]) were included. The primary endpoint of clinical remission was met in 79% at week 8, and 84% at week 16. A total of 42 patients (28%) with prior tofacitinib exposure were included. No significant difference in clinical remission was observed by week 16 between tofacitinib experienced compared to tofacitinib naïve patients (86% vs. 84%, P= 0.67). Complete intestinal ultrasound data was available for 36 patients, showing transmural remission in 64% at week 8 and 81% at week 16, with a decrease in median bowel wall thickness of 2.3 mm and 2.4 mm, respectively.
Conclusions
Upadacitinib resulted in high rates of clinical remission at 8 and 16 weeks in this large real-world cohort of ulcerative colitis patients. Upadacitinib is effective in patients with prior tofacitinib exposure. Intestinal ultrasound shows significant rates of transmural remission at week 8, sustained through week 16.

Citations

Citations to this article as recorded by  
  • Letter: Toward Intra‐Class Switching With JAK Inhibitors?
    Mathieu Uzzan, David Laharie
    Alimentary Pharmacology & Therapeutics.2025; 61(5): 919.     CrossRef
  • 1,641 View
  • 226 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Review
Medication adherence in inflammatory bowel disease
Webber Chan, Andy Chen, Darren Tiao, Christian Selinger, Rupert Leong
Intest Res 2017;15(4):434-445.   Published online October 23, 2017
DOI: https://doi.org/10.5217/ir.2017.15.4.434
AbstractAbstract PDFPubReaderePub

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition with intestinal and extraintestinal manifestations. Medications are the cornerstone of treatment of IBD. However, patients often adhere to medication poorly. Adherence to medications is defined as the process by which patients take their medications as prescribed. Treatment non-adherence is a common problem among chronic diseases, averaging 50% in developed countries and is even poorer in developing countries. In this review, we will examine the adherence data in IBD which vary greatly depending on the study population, route of administration, and methods of adherence measurement used. We will also discuss the adverse clinical outcomes related to non-adherence to medical treatment including increased disease activity, flares, loss of response to anti-tumor necrosis factor therapy, and so forth. There are many methods to measure medication adherence namely direct and indirect methods, each with their advantages and drawbacks. Finally, we will explore different intervention strategies to improve adherence to medications.

Citations

Citations to this article as recorded by  
  • Satisfaction With and Adherence to Off-Label Corticosteroids in Adolescents and Adults With Eosinophilic Esophagitis
    Benjamin D. Gold, Bridgett Goodwin, Kimberly Davis, Carolyn Sweeney, Ryan Ziemiecki, Jeanne Jiang, Tao Fan, Mena Boules, Szu-Ta Chen, David A. Katzka
    Journal of Clinical Gastroenterology.2025; 59(2): 138.     CrossRef
  • Interprofessional approach to personalized medication management and therapy optimization in IBD care
    Daniel Fleischmann, Benedicta Binder, Muriel Huss, Tanja Elger, Claudia Wolf, Johanna Loibl, Hauke Christian Tews, Arne Kandulski, Stephan Schmid, Martina Müller, Alexander Kratzer
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Medication Non-Adherence in Inflammatory Bowel Disease: A Systematic Review Identifying Risk Factors and Opportunities for Intervention
    Kathryn King, Wladyslawa Czuber-Dochan, Trudie Chalder, Christine Norton
    Pharmacy.2025; 13(1): 21.     CrossRef
  • Differences between healthcare practitioners' and patients' perceptions of IBD and its causative factors
    Alexa Duff, Patrick Dawson, Polychronic Pavilidis, Joel Mawdsley
    Gastrointestinal Nursing.2025; 23(1): 21.     CrossRef
  • Despite Increased Disease Activity, Women who Attended a Dedicated Inflammatory Bowel Disease and Pregnancy Clinic Had Infants With Higher Apgar Scores: A Population-Based Study
    Sangmin Lee, Cynthia H Seow, Kara Nerenberg, Stefania Bertazzon, Yvette Leung, Vivian Huang, Tara Whitten, Stephanie Coward, Remo Panaccione, Gilaad G Kaplan, Amy Metcalfe
    Inflammatory Bowel Diseases.2024; 30(7): 1071.     CrossRef
  • Knowledge in Inflammatory Bowel Disease: Translation to Portuguese, Validation, and Clinical Application of the IBD-KNOW Questionnaire
    Cristiana Sequeira, Mariana Coelho, Inês Costa Santos, Sara Ramos Lopes, Cristina Teixeira, João Mangualde, Isabelle Cremers, Ana Paula Oliveira
    GE - Portuguese Journal of Gastroenterology.2024; 31(4): 246.     CrossRef
  • Understanding Medication Nonadherence in Crohn’s Disease Patients: A Qualitative Evaluation
    Robert E Brady, Jessica K Salwen-Deremer, Natalie C Tunnell, Michael W Winter
    Inflammatory Bowel Diseases.2024; 30(11): 2046.     CrossRef
  • Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes
    Carly J. Paoli, Jörg Linder, Khushboo Gurjar, Deepika Thakur, Julie Wyckmans, Stacy Grieve
    Journal of Health Economics and Outcomes Research.2024;[Epub]     CrossRef
  • Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes
    Carly Paoli, Jörg Linder, Khushboo Gurjar, Deepika Thakur, Julie Wyckmans, Stacy Grieve
    Journal of Health Economics and Outcomes Research.2024; : 8.     CrossRef
  • Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO‐ASSIST study)
    Bernd Bokemeyer, Sandra Plachta‐Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
    Alimentary Pharmacology & Therapeutics.2024; 59(9): 1082.     CrossRef
  • How can we improve the carbon footprint of IBD clinical care?
    Isabel Carbery, Gauraang Bhatnagar, Rachel Cooney, Christian Selinger
    Frontline Gastroenterology.2024; 15(e1): e55.     CrossRef
  • Unmet needs of drugs for irritable bowel syndrome and inflammatory bowel diseases: interest of vagus nerve stimulation and hypnosis
    Bruno Bonaz
    Inflammopharmacology.2024; 32(2): 1005.     CrossRef
  • High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease
    Esma H. San, Angelique Egberts, Caroline W. Th. van Dijck - van Boetzelaer, Rachel L. West, Erwin C. Vasbinder
    European Journal of Clinical Pharmacology.2024; 80(7): 1089.     CrossRef
  • Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
    Obreniokibo Amiesimaka, Kristina Aluzaite, Rhiannon Braund, Michael Schultz
    Patient Preference and Adherence.2024; Volume 18: 905.     CrossRef
  • How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer
    Avisek Majumder, Shabana Bano
    Biomolecules.2024; 14(6): 633.     CrossRef
  • Exploring the foundations of a digital health information service for patients with inflammatory bowel disease: a mixed method study in Gravitate-Health
    Sigurd Maurud, Lene Lunde, Anne Moen, Randi Opheim
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Influence of multidisciplinary team care with abundant nurse staffing on patient-reported outcomes among patients with inflammatory bowel disease in clinical remission
    Makoto Tanaka, Aki Kawakami, Kayoko Sakagami, Tomoko Terai, Hiroaki ito
    Health and Quality of Life Outcomes.2024;[Epub]     CrossRef
  • Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions
    Caterina Mercuri, Maria Catone, Vincenzo Bosco, Assunta Guillari, Teresa Rea, Patrizia Doldo, Silvio Simeone
    Healthcare.2024; 12(12): 1210.     CrossRef
  • Effect of Curcumin Plus Piperine on Redox Imbalance, Fecal Calprotectin and Cytokine Levels in Inflammatory Bowel Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Amylly Sanuelly da Paz Martins, Orlando Roberto Pimentel de Araújo, Amanda da Silva Gomes, Fernanda Lívia Cavalcante Araujo, José Oliveira Junior, Joice Kelly Gomes de Vasconcelos, José Israel Rodrigues Junior, Islany Thaissa Cerqueira, Manoel Álvaro de F
    Pharmaceuticals.2024; 17(7): 849.     CrossRef
  • What aspects do we overlook in the rehabilitation of patients with inflammatory bowel disease?
    Benil Nesli Ata, Sibel Eyigor
    World Journal of Gastroenterology.2024; 30(27): 3268.     CrossRef
  • Fournier's Gangrene Associated With Untreated Crohn’s Disease in a Male Patient: A Case Report and Review of the Literature
    Nicos Kritharides, Marios Fouzas, Afroditi Stoupa, Spyridoula Sakkoula, Loukia Prounia - Alexopoulou, Georgios Rallis, Aikaterini Leventi
    Cureus.2024;[Epub]     CrossRef
  • Enhancing self-management of patients with inflammatory bowel disease: the role of autonomy support in health goal pursuit
    Barbara Horvát, Kata Orbán, Anett Dávid, Viola Sallay, Beatrix Rafael, Sanela Njers, Tamás Molnár, Márta Csabai, Georgina Csordás, Tamás Martos
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Adherence to infliximab treatment in patients with immune-mediated inflammatory diseases from a referral center in Brazil: a cohort study
    Priscila Moreira Lauton, Fernanda Silva Pereira, Livia Brito Oliveira, Alline Mikaelle Nunes Wildemberg Brauer, Lucia de Araújo Costa Beisl Noblat, Genoile Oliveira Santana, Pablo Moura Santos
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target
    Akhilesh Swaminathan, Andrew S. Day, Miles P. Sparrow, Laurent Peyrin‐Biroulet, Corey A. Siegel, Richard B. Gearry
    Alimentary Pharmacology & Therapeutics.2024; 60(9): 1176.     CrossRef
  • Refractory Crohn’s Disease: Perspectives, Unmet Needs and Innovations
    Luisa Bertin, Martina Crepaldi, Miriana Zanconato, Greta Lorenzon, Daria Maniero, Caterina De Barba, Erica Bonazzi, Sonia Facchin, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Andrea Buda, Fabiana Zingone, Edoardo Vincenzo Savarino, Brigida Barberio
    Clinical and Experimental Gastroenterology.2024; Volume 17: 261.     CrossRef
  • Diagnostic and Therapeutic Microbial Circuit with Application to Intestinal Inflammation
    Liana N. Merk, Andrey S. Shur, Smrutiti Jena, Javier Munoz, Douglas K. Brubaker, Richard M. Murray, Leopold N. Green
    ACS Synthetic Biology.2024; 13(12): 3885.     CrossRef
  • Obstacles to Medication Adherence for Patients with Inflammatory Bowel Disease: A Qualitative Study in East China
    Fen Xu, Jingjing Xing, Mingna Fan, Zhiping Zhu, Yan Chen, Wen Hu, Yunxian Zhou
    Patient Preference and Adherence.2024; Volume 18: 2481.     CrossRef
  • The role of clinical pharmacists in chronic disease management: Review
    Mohammed Ziad Aldaajani, ‏Abdulmajeed Muhayya Almutairi, Eissa Homuday Almuteriee, ‏Abdullah Saleh Almorshed, ‏Abdullah Abdulrahman Alrbian, ‏Majed Suliman Alwalie, ‏Faleh Mohammed Al Dawsar, Manar Ibrahem Alwehaibi, Mohammed Mesfer Musaed Al Khathami, No
    International journal of health sciences.2024; 8(S1): 1766.     CrossRef
  • Real-World Effectiveness and Safety of Carotegrast Methyl in Japanese Patients with Moderately Active Ulcerative Colitis
    Toshihide Ohmori
    Inflammatory Intestinal Diseases.2024; 9(1): 271.     CrossRef
  • Prediction of the Short-Term Effectiveness of Ustekinumab in Patients with Moderate to Severe Crohn’s Disease
    Tao Su, Ling Liu, Fan Meng, Hongzhen Wu, Tao Liu, Jun Deng, Xiang Peng, Min Zhi, Jiayin Yao
    Journal of Inflammation Research.2024; Volume 17: 9181.     CrossRef
  • Factors influencing medication adherence among patients with idiopathic inflammatory bowel disease in Greece and Cyprus: a cross-sectional study
    Anastasia N. Nicolaou, Maria Saridi, Evangelos C. Fradelos, Ioannis P. Kaimakliotis, Konstantinos Giannakou, Konstantinos H. Katsanos, Stavroula A. Apostolidou
    Polski Merkuriusz Lekarski.2024; 52(5): 489.     CrossRef
  • Psychological Factors Associated With Adherence to Oral Treatment in Ulcerative Colitis
    Sonya S Dasharathy, Millie D Long, Jeffrey M Lackner, Dana Ben-Ami Shor, Liu Yang, Nir Bar, Christina Ha, Guy A Weiss
    Inflammatory Bowel Diseases.2023; 29(1): 97.     CrossRef
  • Development of an Inflammatory Bowel Disease-Specific Medication Adherence Instrument and Reasons for Non-adherence
    Erica J. Brenner, Millie D. Long, Michael D. Kappelman, Xian Zhang, Robert S. Sandler, Edward L. Barnes
    Digestive Diseases and Sciences.2023; 68(1): 58.     CrossRef
  • Impact of a pharmacist‐led thiopurine monitoring service in outpatients with inflammatory bowel disease
    Sheridan E. Rodda, Karina J. Fildes, Edward Shelton, Rimma Goldberg, Gregory T. Moore
    Internal Medicine Journal.2023; 53(5): 779.     CrossRef
  • Modulating the Microbiome for Crohn’s Disease Treatment
    Rachael Gowen, Ahmed Gamal, Luca Di Martino, Thomas S. McCormick, Mahmoud A. Ghannoum
    Gastroenterology.2023; 164(5): 828.     CrossRef
  • The level of adherence to best-practice guidelines by interprofessional teams with and without acute care nurse practitioners in cardiac surgery: A study protocol
    Li-Anne Audet, Mélanie Lavoie-Tremblay, Éric Tchouaket, Kelley Kilpatrick, Robert Jeenchen Chen
    PLOS ONE.2023; 18(3): e0282467.     CrossRef
  • Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States
    Theresa Hunter Gibble, April N. Naegeli, Michael Grabner, Keith Isenberg, Mingyang Shan, Chia-Chen Teng, Jeffrey R. Curtis
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
    Kenneth Ernest-Suarez, Remo Panaccione
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
    Edward V. Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace, Sujani Nannapaneni, Ji Zhou, Rachel Byrne, Kristina Kligys, Yinuo Pang, Xiaomei Liao, Jasmina Kalabic, Marla Dubinsky
    Advances in Therapy.2023; 40(5): 2311.     CrossRef
  • Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
    Tsvetelina H. Baryakova, Brett H. Pogostin, Robert Langer, Kevin J. McHugh
    Nature Reviews Drug Discovery.2023; 22(5): 387.     CrossRef
  • Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
    Ole Haagen Nielsen, Theresa Louise Boye, John Gubatan, Deepavali Chakravarti, James B. Jaquith, Eric C. LaCasse
    Pharmacology & Therapeutics.2023; 245: 108402.     CrossRef
  • Health Communication Research Informs Inflammatory Bowel Disease Practice and Research: A Narrative Review
    Neda Karimi, Alison Rotha Moore, Annabelle Lukin, Susan J Connor
    Crohn's & Colitis 360.2023;[Epub]     CrossRef
  • Medication Adherence Rates in Adolescents With Eosinophilic Esophagitis Are Low and Are Associated With Health Habits
    Pooja Mehta, Zhaoxing Pan, Wenru Zhou, Bethany M. Kwan, Glenn T. Furuta
    Journal of Pediatric Gastroenterology & Nutrition.2023; 77(4): 532.     CrossRef
  • “It's just like putting your socks on”: patients' perspectives on inflammatory bowel disease medication adherence
    Obreniokibo Ibifubara Amiesimaka, Kristina Aluzaite, Rhiannon Braund, Michael Schultz
    Exploratory Research in Clinical and Social Pharmacy.2023; 12: 100385.     CrossRef
  • Non-invasive vagus nerve stimulation: the future of inflammatory bowel disease treatment?
    Bruno Bonaz
    Bioelectronic Medicine.2023;[Epub]     CrossRef
  • What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
    Kathryn King, Serena McGuinness, Natalie Watson, Christine Norton, Trudie Chalder, Wladyslawa Czuber-Dochan
    Patient Preference and Adherence.2023; Volume 17: 3265.     CrossRef
  • Impact of an intervention program on drug adherence in patients with ulcerative colitis: Randomized clinical trial
    Mila Pacheco, Pedro Sá, Gláucia Santos, Ney Boa-Sorte, Kilma Domingues, Larissa Assis, Marina Silva, Ana Oliveira, Daniel Santos, Jamile Ferreira, Rosemeire Fernandes, Flora Fortes, Raquel Rocha, Genoile Santana, Wan-Long Chuang
    PLOS ONE.2023; 18(12): e0295832.     CrossRef
  • Interventions to improve medication adherence in inflammatory bowel disease: A systematic review
    Shrey Gohil, Zahra Majd, Jared C. Sheneman, Susan M. Abughosh
    Patient Education and Counseling.2022; 105(7): 1731.     CrossRef
  • Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study
    Mohammed El-Dallal, Ariana Saroufim, Hannah Systrom, Sarah Ballou, Adel Farhoud, Ravi Teja Pasam, Salini Samyuktha Gadupudi, Karim Osman, Khadija Chaudrey, Adam Cheifetz, Joseph D. Feuerstein
    Scandinavian Journal of Gastroenterology.2022; 57(4): 406.     CrossRef
  • Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study
    Chung Sang Tse, Corey A Siegel, S Alandra Weaver, Brant J Oliver, Catherine Bresee, Welmoed K van Deen, Gil Y Melmed
    Inflammatory Bowel Diseases.2022; 28(10): 1565.     CrossRef
  • Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease
    Neha Shrestha, Yining Xu, Julien R.C. Prévost, Fiona McCartney, David Brayden, Raphaël Frédérick, Ana Beloqui, Véronique Préat
    Acta Biomaterialia.2022; 140: 561.     CrossRef
  • Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
    Edouard Louis
    Inflammatory Intestinal Diseases.2022; 7(1): 64.     CrossRef
  • Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn’s disease patients
    Nathaniel A. Cohen, Dejan M. Micic, Atsushi Sakuraba
    Annals of Medicine.2022; 54(1): 886.     CrossRef
  • Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
    Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, Benjamin Cohen, Timothy Ritter, Bruce Sands, Corey Siegel, John Valentine, Michelle Smith, Niels Vande Casteele, Marla Dubinsky, Adam Cheifetz
    BMJ Open.2022; 12(4): e057656.     CrossRef
  • Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China
    Fen Xu, Juping Tang, Zhiping Zhu, Yan Chen, Wen Hu, Sha Lu, Yunxian Zhou, Ding Lin
    International Journal of General Medicine.2022; Volume 15: 4141.     CrossRef
  • Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases
    Janvi Sah, Amanda Teeple, Erik Muser, Cynthia Gutierrez, Themistocles Dassopoulos
    Current Medical Research and Opinion.2022; 38(7): 1093.     CrossRef
  • Psychological Effects and Medication Adherence among Korean Patients with Inflammatory Bowel Disease during the Coronavirus Disease 2019 Pandemic: A Single-Center Survey
    Ji Eun Ryu, Sung-Goo Kang, Sung Hoon Jung, Shin Hee Lee, Sang-Bum Kang
    Journal of Clinical Medicine.2022; 11(11): 3034.     CrossRef
  • Factors influencing poor medication adherence amongst patients with chronic disease in low-and-middle-income countries: A systematic scoping review
    Gloria Dunisani Chauke, Olivia Nakwafila, Buyisile Chibi, Benn Sartorius, Tivani Mashamba-Thompson
    Heliyon.2022; 8(6): e09716.     CrossRef
  • Rational Design of Self-Emulsifying Pellet Formulation of Thymol: Technology Development Guided by Molecular-Level Structure Characterization and Ex Vivo Testing
    Jan Macku, Katerina Kubova, Martina Urbanova, Jan Muselik, Ales Franc, Gabriela Koutna, Miroslava Pavelkova, David Vetchy, Josef Masek, Eliska Maskova, Jiri Brus
    Pharmaceutics.2022; 14(8): 1545.     CrossRef
  • Poor Adherence to Medical and Dietary Treatments in Adult Patients With Eosinophilic Esophagitis
    Maria L. Haasnoot, Salma Safi, Albert J. Bredenoord
    American Journal of Gastroenterology.2022; 117(9): 1412.     CrossRef
  • Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis
    Jae Song Kim, Min Jung Geum, Eun Sun Son, Yun Mi Yu, Jae Hee Cheon, Kyeng Hee Kwon
    Gut and Liver.2022; 16(5): 736.     CrossRef
  • Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries
    Sarah Bentley, Lucy Morgan, Elizabeth Exall, Rob Arbuckle, Rebecca C Rossom, Nicholas Roche, Kamlesh Khunti, Victoria Higgins, James Piercy
    Patient Preference and Adherence.2022; Volume 16: 2579.     CrossRef
  • Electrical neuromodulation therapy for inflammatory bowel disease
    Farah Yasmin, Abdul Moiz Sahito, Syeda Lamiya Mir, Govinda Khatri, Somina Shaikh, Ambresha Gul, Syed Adeel Hassan, Thoyaja Koritala, Salim Surani
    World Journal of Gastrointestinal Pathophysiology.2022; 13(5): 128.     CrossRef
  • Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores
    Eva-Maria Messner, Niklas Sturm, Yannik Terhorst, Lasse B Sander, Dana Schultchen, Alexandra Portenhauser, Simone Schmidbaur, Michael Stach, Jochen Klaus, Harald Baumeister, Benjamin M Walter
    Journal of Medical Internet Research.2022; 24(10): e37497.     CrossRef
  • A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial
    Jordan Axelrad, Millie Long, Sara Horst, Anita Afzali, Tamar Sapir, Kristina Fajardo, Kara De Felice, Robert Sandler, Raymond Cross
    JMIR Research Protocols.2022; 11(12): e40382.     CrossRef
  • Medication adherence in women with IBD of childbearing age likely associated with disease knowledge
    Robyn Laube, Christian Selinger, Rupert W. Leong
    Therapeutic Advances in Gastroenterology.2022;[Epub]     CrossRef
  • Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies
    Qian Cai, Zhijie Ding, Alex Z. Fu, Aarti A. Patel
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: Attitudinal perspectives among Turkish population
    Soner Guven, Mehmet Talay Koylu, Tarkan Mumcuoglu
    European Journal of Ophthalmology.2021; 31(2): 469.     CrossRef
  • Utility of the MARS-5 in Assessing Medication Adherence in IBD
    James K Stone, Leigh Anne Shafer, Lesley A Graff, Lisa Lix, Kelcie Witges, Laura E Targownik, Clove Haviva, Kathryn Sexton, Charles N Bernstein
    Inflammatory Bowel Diseases.2021; 27(3): 317.     CrossRef
  • Curcumin and inflammatory bowel diseases: From in vitro studies to clinical trials
    Farzaneh Fallahi, Sarina Borran, Milad Ashrafizadeh, Ali Zarrabi, Mohammad Hossein Pourhanifeh, Mahmood Khaksary Mahabady, Amirhossein Sahebkar, Hamed Mirzaei
    Molecular Immunology.2021; 130: 20.     CrossRef
  • Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real‐world data
    Marios Rossides, Susanna Kullberg, Daniela Di Giuseppe, Anders Eklund, Johan Grunewald, Johan Askling, Elizabeth V. Arkema
    Respirology.2021; 26(5): 452.     CrossRef
  • Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review
    Juan C Nieto, Claudia Arajol, Loreto Carmona, Carlos Marras, Luis Cea-Calvo
    Immunotherapy.2021; 13(5): 433.     CrossRef
  • Digital Medication Adherence Support: Could Healthcare Providers Recommend Mobile Health Apps?
    Claudine Backes, Carla Moyano, Camille Rimaud, Christine Bienvenu, Marie P. Schneider
    Frontiers in Medical Technology.2021;[Epub]     CrossRef
  • Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases
    Bruno Bonaz, Valérie Sinniger, Sonia Pellissier
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
    Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
    Journal of Coloproctology.2021; 41(01): 096.     CrossRef
  • JAK1 inhibition and inflammatory bowel disease
    Clare Harris, J R Fraser Cummings
    Rheumatology.2021; 60(Supplement): ii45.     CrossRef
  • Effect of point‐of‐care gastrointestinal ultrasound on decision‐making and management in inflammatory bowel disease
    Antony B. Friedman, Anil Asthana, Simon R. Knowles, Aphra Robbins, Peter R. Gibson
    Alimentary Pharmacology & Therapeutics.2021; 54(5): 652.     CrossRef
  • Factors Associated with Medication Non-Adherence in Patients with Dyslipidemia
    Eman Alefishat, Anan S. Jarab, Walid Al-Qerem, Lina Abu-Zaytoun
    Healthcare.2021; 9(7): 813.     CrossRef
  • Systematic review with meta‐analysis: dietary intake in adults with inflammatory bowel disease
    Kelly Lambert, Daniel Pappas, Chiara Miglioretto, Arefeh Javadpour, Hannah Reveley, Laura Frank, Michael C. Grimm, Dorit Samocha‐Bonet, Georgina L. Hold
    Alimentary Pharmacology & Therapeutics.2021; 54(6): 742.     CrossRef
  • Patients’ perspectives on medication for inflammatory bowel disease: a mixed-method systematic review
    José Diego Marques Santos, Juan Nicolás Peña-Sánchez, Sharyle A. Fowler
    European Journal of Gastroenterology & Hepatology.2021; 33(9): 1139.     CrossRef
  • Adherence to treatment of patients with irritable bowel syndrome: state of the issue
    S.A. Sukhanova, A.Yu. Timakova, M.A. Livzan, M.M. Fedorin, Yu.P. Skirdenko, O.V. Gaus, K.A. Andreev, A.V. Gorbenko, M.I. Plinder
    Profilakticheskaya meditsina.2021; 24(8): 101.     CrossRef
  • Adherence to Inflammatory Bowel Disease Medications in Southern New Zealand
    Kristina Aluzaite, Rhiannon Braund, Liam Seeley, Obreniokibo Ibifubara Amiesimaka, Michael Schultz
    Crohn's & Colitis 360.2021;[Epub]     CrossRef
  • Impact of Demographic, Clinical and Psychosocial Variables on Drug Adherence and Outcomes in Indian Patients With Inflammatory Bowel Disease
    Rupa Banerjee, Partha Pal, Bhargavi Adigopula, Duvvuru Nageshwar Reddy
    Journal of Clinical Gastroenterology.2021; 55(10): e92.     CrossRef
  • Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use
    Danielle Bargo, Theo Tritton, Joseph C. Cappelleri, Marco DiBonaventura, Timothy W. Smith, Takanori Tsuchiya, Sean Gardiner, Irene Modesto, Tim Holbrook, Daniel Bluff, Taku Kobayashi
    Inflammatory Intestinal Diseases.2021; 6(4): 186.     CrossRef
  • Impact of pain associated with the subcutaneous administration of adalimumab
    Cristina Gely, Laura Marín, Jordi Gordillo, Míriam Mañosa, Federico Bertoletti, Fiorella Cañete, Carlos González-Muñoza, Margalida Calafat, Eugeni Domènech, Esther Garcia-Planella
    Gastroenterología y Hepatología.2020; 43(1): 9.     CrossRef
  • Patient Perspectives on Short-Course Pharmacotherapy: Barriers and Facilitators to Medication Adherence
    LeeAnne B Sherwin, Diana Ross, Michelle Matteson-Kome, Matthew Bechtold, Chelsea Deroche, Bonnie Wakefield
    Journal of Patient Experience.2020; 7(5): 726.     CrossRef
  • Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications
    Sangmin Lee, Cynthia H. Seow, Kamala Adhikari, Amy Metcalfe
    Alimentary Pharmacology & Therapeutics.2020; 51(5): 544.     CrossRef
  • Encuesta de adherencia al tratamiento en enfermedad inflamatoria intestinal. Estudio ENADEII
    Inmaculada Alonso-Abreu, Onofre Alarcón-Fernández, Marta Carrillo-Palau, Laura Ramos-López, Javier P. Gisbert, María Chaparro, Pilar Nos, Alejandro Jiménez, Enrique Quintero-Carrión
    Gastroenterología y Hepatología.2020; 43(6): 285.     CrossRef
  • Impact of pain associated with the subcutaneous administration of adalimumab
    Cristina Gely, Laura Marín, Jordi Gordillo, Míriam Mañosa, Federico Bertoletti, Fiorella Cañete, Carlos González-Muñoza, Margalida Calafat, Eugeni Domènech, Esther Garcia-Planella
    Gastroenterología y Hepatología (English Edition).2020; 43(1): 9.     CrossRef
  • Challenges and Approaches to Assessing Medication Adherence in Pediatric Inflammatory Bowel Diseases
    David H. Barker, Jason M. Shapiro, Debra Lobato, Elizabeth L. McQuaid, Neal S. Leleiko
    Journal of Pediatric Gastroenterology and Nutrition.2020; 70(6): 759.     CrossRef
  • A 12‐month pilot study outcomes of vagus nerve stimulation in Crohn's disease
    Valérie Sinniger, Sonia Pellissier, Florence Fauvelle, Candice Trocmé, Dominique Hoffmann, Laurent Vercueil, Jean‐Luc Cracowski, Olivier David, Bruno Bonaz
    Neurogastroenterology & Motility.2020;[Epub]     CrossRef
  • Survey of adherence to treatment in inflammatory bowel disease. ENADEII study
    Inmaculada Alonso-Abreu, Onofre Alarcón-Fernández, Marta Carrillo-Palau, Laura Ramos-López, Javier Pérez Gisbert, María Chaparro, Pilar Nos, Alejandro Jiménez, Enrique Quintero-Carrión
    Gastroenterología y Hepatología (English Edition).2020; 43(6): 285.     CrossRef
  • Adherence to exclusive enteral nutrition by adults with active Crohn’s disease is associated with conscientiousness personality trait: a sub‐study
    C. L. Wall, A. McCombie, R. Mulder, A. S. Day, R. B. Gearry
    Journal of Human Nutrition and Dietetics.2020; 33(6): 752.     CrossRef
  • Maytenus robusta Reissek, a medicinal plant popularly used to treat digestive diseases, promotes ameliorative effects in colon and liver of mice exposed to dextran sulfate sodium
    Mariéli Mees, Marianne Caroline Meurer, Luísa Nathalia Bolda Mariano, Thaise Boeing, Lincon Bordignon Somensi, Marihá Mariott, Rivaldo Niero, Valdir Cechinel-Filho, Sérgio Faloni de Andrade, Lucienir Pains Duarte, Grasiely Faria de Sousa, Priscila de Souz
    Journal of Ethnopharmacology.2020; : 113180.     CrossRef
  • A Micro‐longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel Diseases
    Jill M. Plevinsky, Lee A. Denson, Jenny Hellmann, Phillip Minar, Michael J. Rosen, Kevin A. Hommel
    Journal of Pediatric Gastroenterology and Nutrition.2020; 71(3): 366.     CrossRef
  • Emulsifiers Impact Colonic Length in Mice and Emulsifier Restriction is Feasible in People with Crohn’s Disease
    Alicia M. Sandall, Selina R. Cox, James O. Lindsay, Andrew T. Gewirtz, Benoit Chassaing, Megan Rossi, Kevin Whelan
    Nutrients.2020; 12(9): 2827.     CrossRef
  • Adherence to Medical Treatment in Inflammatory Bowel Disease Patients from a Referral Center in Bahia‐Brazil
    Laíla D. Andrade, Fernanda A. Oliveira, Victor D. Mariano, Monique C. A. Santos, Fernanda A. Pereira, Cláudia I. N. dos Santos, Flora M. L. Fortes, Andrea M. Pimentel, Jaciane A. Mota, Neogélia P. Almeida, Valdiana C. Surlo, Bruno C. Silva, Mila P. Pachec
    BioMed Research International.2020;[Epub]     CrossRef
  • A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review
    Sharmila S. Prasad, Kerith Duncanson, Simon Keely, Nicholas J. Talley, Therése Kairuz, Gerald J. Holtmann, Ayesha Shah, Marjorie M. Walker
    Pharmacy.2020; 8(4): 204.     CrossRef
  • Self-assessment of treatment targets in patients with inflammatory bowel disease using a survey
    Philipp A. Reuken, Philip C. Grunert, Andreas Lügering, Niels Teich, Andreas Stallmach
    Therapeutic Advances in Gastroenterology.2020;[Epub]     CrossRef
  • Longitudinal Barriers to Thiopurine Adherence in Adolescents With Inflammatory Bowel Diseases
    Jill M Plevinsky, Andrea A Wojtowicz, Steven A Miller, Rachel N Greenley
    Journal of Pediatric Psychology.2019; 44(1): 52.     CrossRef
  • Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
    Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
    Intestinal Research.2019; 17(3): 349.     CrossRef
  • Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey
    Steve Fenwick, Kunal Thakur, Duncan Munro
    Rheumatology and Therapy.2019; 6(2): 195.     CrossRef
  • Factors Associated with Adherence to Allergen Specific Subcutaneous Immunotherapy
    Ji-Ho Lee, So-Hee Lee, Ga-Young Ban, Young-Min Ye, Dong-Ho Nahm, Hae-Sim Park, Yoo Seob Shin
    Yonsei Medical Journal.2019; 60(6): 570.     CrossRef
  • Self-Management Through Social Support Among Emerging Adults With Inflammatory Bowel Disease
    Kendra J. Kamp, Zhehui Luo, Amanda Holmstrom, Barbara Given, Gwen Wyatt
    Nursing Research.2019; 68(4): 285.     CrossRef
  • Innovations in Oral Therapies for Inflammatory Bowel Disease
    Christopher Ma, Robert Battat, Parambir S. Dulai, Claire E. Parker, William J. Sandborn, Brian G. Feagan, Vipul Jairath
    Drugs.2019; 79(12): 1321.     CrossRef
  • Longitudinal non‐adherence predicts treatment escalation in paediatric ulcerative colitis
    Julia K. Carmody, Jill Plevinsky, James L. Peugh, Lee A. Denson, Jeffrey S. Hyams, Debra Lobato, Neal S. LeLeiko, Kevin A. Hommel
    Alimentary Pharmacology & Therapeutics.2019; 50(8): 911.     CrossRef
  • The Development of a Screening Tool to Identify and Classify Nonadherence in Inflammatory Bowel Disease
    Aria Zand, Audrey Nguyen, Zack Stokes, Welmoed van Deen, Courtney Reynolds, Magdalena Dimitrova, Ariela Khandadash, Miriam Dvorsky, Jenny Sauk, Eric Esrailian, Daniel Hommes
    Crohn's & Colitis 360.2019;[Epub]     CrossRef
  • British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
    Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm
    Gut.2019; 68(Suppl 3): s1.     CrossRef
  • Treatment of inflammatory bowel disease via green tea polyphenols: possible application and protective approaches
    Sajid Ur Rahman, Yu Li, Yingying Huang, Lei Zhu, Shibin Feng, Jinjie Wu, Xichun Wang
    Inflammopharmacology.2018; 26(2): 319.     CrossRef
  • A RARE CASE OF CROHN DISEASE COMPLICATED WITH STEROID MONOTHERAPY-RELATED RETROPHARYNGEAL ABSCESS AND INITIALLY MISINTERPRETED PYODERMA GANGRENOSUM DEVELOPMENT
    Michael Doulberis, Jörg Dähn, Jannis Kountouras, Volker Maier, Arthur Helbling, Patrick Dubach
    Gastroenterology Nursing.2018; 41(4): 347.     CrossRef
  • Clinical usefulness of remote patient monitoring using e-Health technologies in patients with inflammatory bowel diseases
    Sung Noh Hong
    The Korean Journal of Internal Medicine.2018; 33(5): 876.     CrossRef
  • Is Curcumin a Possibility to Treat Inflammatory Bowel Diseases?
    Rafaela Mazieiro, Renata Reis Frizon, Sandra Maria Barbalho, Ricardo de Alvares Goulart
    Journal of Medicinal Food.2018; 21(11): 1077.     CrossRef
  • Brazilian green propolis hydroalcoholic extract reduces colon damages caused by dextran sulfate sodium-induced colitis in mice
    Luisa Nathália Bolda Mariano, Caroline Arruda, Lincon Bordignon Somensi, Ana Paula Michels Costa, Eduardo Gnoatto Perondi, Thaise Boeing, Marihá Mariott, Rita de Cássia Melo Vilhena de Andr da Silva, Priscila de Souza, Jairo Kenupp Bastos, Sérgio Faloni d
    Inflammopharmacology.2018; 26(5): 1283.     CrossRef
  • Medication non-adherence in inflammatory bowel diseases is associated with disability
    Jonathan Perry, Andy Chen, Viraj Kariyawasam, Glen Collins, Chee Choong, Wei Ling Teh, Nikola Mitrev, Friedbert Kohler, Rupert Wing Loong Leong
    Intestinal Research.2018; 16(4): 571.     CrossRef
  • Adherence to therapy of patients with inflammatory bowel diseases
    A I Parfenov, A V Kagramanova, A F Babayan, O V Knyazev
    Terapevticheskii arkhiv.2018; 90(12): 4.     CrossRef
  • 12,983 View
  • 230 Download
  • 112 Web of Science
  • 115 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP